Back to Agenda
Session 2a: So You Want to Develop a Biosimilar - Defining the Pipeline
Session Chair(s)
Leah Christl, PHD
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy, Amgen, United States
So, you’ve decided to get into the biosimilars business…now what? This session will focus on how manufacturers assess the potential of specific biosimilar assets and make decisions about their future pipeline. The session will address aspects such as asset selection drivers, portfolio considerations, and perspectives to consider related to patents. The session will also discuss the dynamics of penetrating the market, the reality of global biosimilar markets, and future market development.
Learning Objective : - Provide perspective as to why companies choose to develop certain biosimilars
- Identify factors that drive the selection of a biosimilar asset
- Understand the factors that drive decisions by manufacturers to ultimately bring or not bring a biosimilar to the market
- Identify what is on the horizon for the next wave of biosimilar products
- Understand the dynamics of penetrating the biosimilars marketplace
Speaker(s)
Chad Pettit, MBA
Executive Director, Marketing, Global Biosimilars Commercial Lead, Amgen Inc., United States
Speaker
Balaji V Prasad, MD, MBA
Director, Specialty Pharma Equity Research, Barclays, United States
Speaker
Rachel Goode, PHD
Senior Vice President, IP and Legal, Biosimilars , Fresenius Kabi , United States
Speaker
Have an account?